Total Payments
$14,000
2024 Payments
$3,525
Companies
48
Transactions
483
Medicare Patients
1,095
Medicare Billing
$342,747
Payment Breakdown by Category
Food & Beverage$11,910 (85.1%)
Education$1,110 (7.9%)
Other$980.63 (7.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $11,910 | 457 | 85.1% |
| Education | $1,110 | 16 | 7.9% |
| Long term medical supply or device loan | $980.63 | 10 | 7.0% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,175 | 20 | $0 (2024) |
| Merck Sharp & Dohme LLC | $959.27 | 52 | $0 (2024) |
| Janssen Biotech, Inc. | $904.27 | 38 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $794.46 | 33 | $0 (2024) |
| BeiGene USA, Inc. | $747.71 | 12 | $0 (2024) |
| Lilly USA, LLC | $661.99 | 27 | $0 (2024) |
| E.R. Squibb & Sons, L.L.C. | $658.73 | 36 | $0 (2024) |
| Incyte Corporation | $516.08 | 19 | $0 (2024) |
| Eisai Inc. | $511.46 | 25 | $0 (2024) |
| Bayer Healthcare Pharmaceuticals Inc. | $488.93 | 16 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $3,525 | 99 | Novartis Pharmaceuticals Corporation ($1,010) |
| 2023 | $2,812 | 101 | Rigel Pharmaceuticals, Inc. ($250.32) |
| 2022 | $2,327 | 99 | E.R. Squibb & Sons, L.L.C. ($268.62) |
| 2021 | $2,258 | 80 | BeiGene USA, Inc. ($250.00) |
| 2020 | $1,035 | 43 | AstraZeneca Pharmaceuticals LP ($227.32) |
| 2019 | $1,120 | 35 | Abbott Laboratories ($299.44) |
| 2018 | $468.09 | 15 | Boehringer Ingelheim Pharmaceuticals, Inc. ($121.17) |
| 2017 | $454.95 | 11 | Daiichi Sankyo Inc. ($171.51) |
All Payment Transactions
483 individual payment records from CMS Open Payments — Page 1 of 20
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/20/2024 | AstraZeneca Pharmaceuticals LP | TAGRISSO (Drug) | Food and Beverage | In-kind items and services | $19.82 | General |
| Category: Oncology | ||||||
| 12/12/2024 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological), LYNPARZA | Food and Beverage | In-kind items and services | $20.90 | General |
| Category: ONCOLOGY | ||||||
| 12/10/2024 | Exelixis Inc. | CABOMETYX (Drug) | Food and Beverage | In-kind items and services | $14.55 | General |
| Category: Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid Cancer (DTC) | ||||||
| 12/06/2024 | JAZZ PHARMACEUTICALS INC. | ZEPZELCA (Drug) | Food and Beverage | In-kind items and services | $24.50 | General |
| Category: HEMATOLOGY/ONCOLOGY | ||||||
| 12/05/2024 | Novartis Pharmaceuticals Corporation | Fabhalta (Drug) | Food and Beverage | In-kind items and services | $29.47 | General |
| Category: Immunology | ||||||
| 12/03/2024 | Takeda Pharmaceuticals U.S.A., Inc. | ALUNBRIG (Drug) | Food and Beverage | In-kind items and services | $28.56 | General |
| Category: ONCOLOGY | ||||||
| 11/21/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | — | Food and Beverage | In-kind items and services | $21.78 | General |
| 11/20/2024 | Exelixis Inc. | CABOMETYX (Drug) | Food and Beverage | In-kind items and services | $18.67 | General |
| Category: Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid Cancer (DTC) | ||||||
| 11/15/2024 | PFIZER INC. | INLYTA (Drug), PADCEV | Food and Beverage | In-kind items and services | $26.94 | General |
| Category: ONCOLOGY | ||||||
| 11/12/2024 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological), WELIREG | Food and Beverage | In-kind items and services | $14.64 | General |
| Category: ONCOLOGY | ||||||
| 11/11/2024 | GlaxoSmithKline, LLC. | OJJAARA (Drug) | Food and Beverage | In-kind items and services | $20.83 | General |
| Category: ONCOLOGY | ||||||
| 11/08/2024 | GlaxoSmithKline, LLC. | OJJAARA (Drug) | Food and Beverage | In-kind items and services | $18.79 | General |
| Category: ONCOLOGY | ||||||
| 11/07/2024 | AngioDynamics, Inc. | NANOKNIFE (Device) | Food and Beverage | In-kind items and services | $125.00 | General |
| Category: OS | ||||||
| 11/05/2024 | Janssen Biotech, Inc. | ERLEADA (Drug), AKEEGA, BALVERSA | Food and Beverage | In-kind items and services | $15.54 | General |
| Category: Oncology | ||||||
| 10/26/2024 | Janssen Biotech, Inc. | DARZALEX (Biological), TECVAYLI, TALVEY | Food and Beverage | In-kind items and services | $30.15 | General |
| Category: Oncology | ||||||
| 10/24/2024 | Lilly USA, LLC | VERZENIO (Drug), JAYPIRCA | Food and Beverage | In-kind items and services | $18.60 | General |
| Category: Oncology | ||||||
| 10/22/2024 | Exelixis Inc. | CABOMETYX (Drug) | Food and Beverage | In-kind items and services | $17.64 | General |
| Category: Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid Cancer (DTC) | ||||||
| 10/17/2024 | Novartis Pharmaceuticals Corporation | KISQALI (Drug) | Long term medical supply or device loan | In-kind items and services | $83.33 | General |
| Category: Oncology | ||||||
| 10/17/2024 | Agios Pharmaceuticals, Inc. | PYRUKYND (Drug) | Food and Beverage | In-kind items and services | $13.71 | General |
| Category: Genetically Defined Disease | ||||||
| 10/15/2024 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological) | Food and Beverage | In-kind items and services | $20.00 | General |
| Category: ONCOLOGY | ||||||
| 10/10/2024 | Eisai Inc. | Lenvima (Drug) | Food and Beverage | In-kind items and services | $24.75 | General |
| Category: Oncology | ||||||
| 10/09/2024 | Astellas Pharma US Inc | — | Education | In-kind items and services | $99.95 | General |
| 10/03/2024 | Daiichi Sankyo Inc. | Enhertu (Drug) | Food and Beverage | In-kind items and services | $18.44 | General |
| Category: ONCOLOGY | ||||||
| 09/27/2024 | Novartis Pharmaceuticals Corporation | KISQALI (Drug) | Long term medical supply or device loan | In-kind items and services | $99.70 | General |
| Category: Oncology | ||||||
| 09/26/2024 | Mirati Therapeutics, Inc. | KRAZATI (Drug) | Food and Beverage | Cash or cash equivalent | $24.62 | General |
| Category: Oncology | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 9 | 206 | 638 | $91,800 | $46,720 |
| 2022 | 9 | 243 | 824 | $137,375 | $67,406 |
| 2021 | 8 | 346 | 1,193 | $234,685 | $119,369 |
| 2020 | 6 | 300 | 1,114 | $216,375 | $109,252 |
Total Patients
1,095
Total Services
3,769
Medicare Billing
$342,747
Procedure Codes
32
All Medicare Procedures & Services
32 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 56 | 364 | $54,600 | $26,193 | 48.0% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 38 | 42 | $12,600 | $6,525 | 51.8% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 19 | 48 | $7,200 | $3,892 | 54.1% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 15 | 31 | $5,425 | $3,368 | 62.1% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 19 | 23 | $4,600 | $2,669 | 58.0% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 13 | 13 | $3,250 | $2,015 | 62.0% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 13 | 15 | $3,375 | $1,683 | 49.9% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2023 | 22 | 37 | $555.00 | $310.80 | 56.0% |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | Office | 2023 | 11 | 65 | $195.00 | $65.96 | 33.8% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 70 | 521 | $78,150 | $34,510 | 44.2% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 50 | 61 | $18,300 | $11,312 | 61.8% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 23 | 78 | $11,700 | $6,659 | 56.9% |
| 99291 | Critical care, first 30-74 minutes | Facility | 2022 | 14 | 30 | $13,500 | $6,211 | 46.0% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 20 | 31 | $6,200 | $3,425 | 55.2% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 16 | 23 | $4,025 | $2,193 | 54.5% |
| 99222 | Initial hospital inpatient care per day, typically 50 minutes | Facility | 2022 | 12 | 14 | $3,150 | $1,767 | 56.1% |
| 99442 | Telephone medical discussion with physician, 11-20 minutes | Office | 2022 | 12 | 16 | $1,600 | $1,181 | 73.8% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2022 | 26 | 50 | $750.00 | $148.29 | 19.8% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2021 | 120 | 737 | $110,550 | $50,702 | 45.9% |
| 99291 | Critical care delivery critically ill or injured patient, first 30-74 minutes | Facility | 2021 | 32 | 120 | $54,000 | $26,045 | 48.2% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2021 | 89 | 128 | $38,400 | $24,153 | 62.9% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2021 | 38 | 84 | $14,700 | $8,123 | 55.3% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 22 | 59 | $8,850 | $5,139 | 58.1% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Office | 2021 | 15 | 15 | $4,500 | $3,225 | 71.7% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 14 | 16 | $3,175 | $1,880 | 59.2% |
About Dr. Qi Feng, M.D
Dr. Qi Feng, M.D is a Hematology & Oncology healthcare provider based in Brooklyn, New York. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 01/28/2009. The National Provider Identifier (NPI) number assigned to this provider is 1659519650.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Qi Feng, M.D has received a total of $14,000 in payments from pharmaceutical and medical device companies, with $3,525 received in 2024. These payments were reported across 483 transactions from 48 companies. The most common payment nature is "Food and Beverage" ($11,910).
As a Medicare-enrolled provider, Feng has provided services to 1,095 Medicare beneficiaries, totaling 3,769 services with total Medicare billing of $342,747. Data is available for 4 years (2020–2023), covering 32 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology & Oncology
- Location Brooklyn, NY
- Active Since 01/28/2009
- Last Updated 04/24/2025
- Taxonomy Code 207RH0003X
- Entity Type Individual
- NPI Number 1659519650
Products in Payments
- KISQALI (Drug) $1,001
- KEYTRUDA (Biological) $892.45
- BRUKINSA (Drug) $747.71
- Lenvima (Drug) $495.89
- TAGRISSO (Drug) $438.30
- ERLEADA (Drug) $395.68
- Stivarga (Drug) $380.05
- OPDIVO (Biological) $356.40
- Rezlidhia (Drug) $320.53
- CABOMETYX (Drug) $267.80
- VERZENIO (Drug) $267.16
- Doptelet (Drug) $241.98
- JAKAFI (Drug) $236.70
- DARZALEX (Biological) $219.35
- INLYTA (Drug) $216.06
- Tavalisse (Drug) $160.16
- LIBTAYO (Biological) $157.36
- CYRAMZA (Drug) $154.88
- IMFINZI (Drug) $153.84
- Absolute Pro vascular stent system (Device) $149.26
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Hematology & Oncology Doctors in Brooklyn
Perry Cook, M.d, M.D
Hematology & Oncology — Payments: $1.4M
Hematology & Oncology $1.4M
Yiwu Huang, Md, MD
Hematology & Oncology — Payments: $268,275
Hematology & Oncology $268,275
Dr. Ilya Blokh, M.d, M.D
Hematology & Oncology — Payments: $191,276
Hematology & Oncology $191,276
Songchuan Guo, M.d, M.D
Hematology & Oncology — Payments: $106,907
Hematology & Oncology $106,907
Yiqing Xu, Md, Phd, MD, PHD
Hematology & Oncology — Payments: $51,145
Hematology & Oncology $51,145
Dr. Azriel Hirschfeld, M.d, M.D
Hematology & Oncology — Payments: $48,699
Hematology & Oncology $48,699